

CARACO PHARMACEUTICAL LABORATORIES LTD  
 Form 4  
 April 01, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 MOVENS DANIEL H

2. Issuer Name and Ticker or Trading Symbol  
 CARACO PHARMACEUTICAL LABORATORIES LTD [CPD]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 03/28/2008

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chief Executive Officer

1150 ELIJAH MCCOY DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

DETROIT, MI 48202

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	03/28/2008		S <sup>(1)</sup>	200 D \$ 17.33	44,800	D	
Common Stock	03/28/2008		S <sup>(1)</sup>	100 D \$ 17.34	44,700	D	
Common Stock	03/28/2008		S <sup>(1)</sup>	100 D \$ 17.43	44,600	D	
Common Stock	03/28/2008		S <sup>(1)</sup>	364 D \$ 17.45	44,236	D	
Common Stock	03/28/2008		S <sup>(1)</sup>	100 D \$ 17.47	44,136	D	

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	200	D	\$ 17.48	43,936	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	200	D	\$ 17.49	43,736	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	300	D	\$ 17.5	43,436	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	200	D	\$ 17.51	43,236	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	100	D	\$ 17.52	44,136	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	131	D	\$ 17.53	43,005	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	69	D	\$ 17.54	42,936	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	200	D	\$ 17.55	42,736	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	100	D	\$ 17.56	42,636	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	800	D	\$ 17.57	41,836	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	400	D	\$ 17.58	41,436	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	500	D	\$ 17.59	40,936	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	636	D	\$ 17.6	40,300	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	100	D	\$ 17.61	40,200	D
Common Stock	03/28/2008	<u>S<sup>(1)</sup></u>	200	D	\$ 17.67	40,000	D
Common Stock	03/31/2008	<u>S<sup>(1)</sup></u>	200	D	\$ 17.47	39,800	D
Common Stock	03/31/2008	<u>S<sup>(1)</sup></u>	100	D	\$ 17.59	39,700	D
Common Stock	03/31/2008	<u>S<sup>(1)</sup></u>	200	D	\$ 17.62	39,500	D
Common Stock	03/31/2008	<u>S<sup>(1)</sup></u>	400	D	\$ 17.65	39,100	D
Common Stock	03/31/2008	<u>S<sup>(1)</sup></u>	200	D	\$ 17.67	38,900	D
	03/31/2008	<u>S<sup>(1)</sup></u>	300	D		38,600	D

Common Stock						\$ 17.75		
Common Stock	03/31/2008	S <sup>(1)</sup>	800	D		\$ 17.76	37,800	D
Common Stock	03/31/2008	S <sup>(1)</sup>	100	D		\$ 17.8	37,700	D
Common Stock	03/31/2008	S <sup>(1)</sup>	475	D		\$ 17.81	37,225	D
Common Stock	03/31/2008	S <sup>(1)</sup>	100	D		\$ 17.84	37,125	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Beneficially (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MOVENS DANIEL H 1150 ELIJAH MCCOY DRIVE DETROIT, MI 48202	X		Chief Executive Officer	

## Signatures

Fred B. Green as attorney-in-fact  
04/01/2008

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 14, 2008, the reporting person entered into a Rule 10b5-1 trading plan to sell up to 30,000 shares of common stock for estate and tax planning objectives. The reported sales were effected pursuant to such Rule 10b5-1 plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.